On August 14, 2026, the U.S. District Court for the District of Massachusetts vacated the provision of a Trump administration rule that would have removed certain gender-affirming care from the Affordable Care Act‘s essential health benefit categories. The court found the change was made without a procedure federal law requires.
The decision is narrow in a way that matters, and it lands in the middle of a busy year for transgender health policy — a subject we track in depth across our Transgender History & Education hub. What follows is a fact-based account of what the court did, what it declined to do, and what remains unsettled, drawn from the ruling itself and from the offices that litigated it.
What did the court actually decide?
The court struck down one provision of the “Marketplace Integrity and Affordability” rule — the piece that would have excluded certain types of gender-affirming care from the ACA’s list of essential health benefits.
The Trump administration proposed the rule in March 2025 and finalized it later that year. According to the Massachusetts Attorney General’s Office, it was presented as a measure to curb alleged ACA enrollment fraud and reduce federal spending on the subsidies that help consumers afford marketplace coverage. Among its many changes, it would have removed certain gender-affirming services from the ACA’s ten essential health benefit categories.
The order came from U.S. District Judge Nathaniel Gorton. Vacating the provision means it is wiped from the books rather than merely paused for the parties in the case — a different remedy from the temporary stays and preliminary injunctions that have characterized much of this year’s litigation.
What are “essential health benefits,” and why does the label matter?
Essential health benefits are the ten categories of care that most individual and small-group plans must cover under the ACA, and the label carries specific financial consequences.
The distinction is more than insurance vocabulary. Spending on essential health benefits counts toward the law’s annual out-of-pocket maximum, and those benefits cannot carry annual or lifetime dollar caps. Under the vacated policy, insurers could still have covered gender-affirming care voluntarily, and states could still have mandated it — but the care would have sat outside those protections.
In practice, as Healthcare Dive reported, that would mean a patient receiving recurring prescriptions, laboratory monitoring, or follow-up care could keep paying out of pocket even after hitting the plan’s ordinary annual ceiling, depending on how a given claim was classified. Higher costs, the outlet noted, can interrupt treatment or lead patients to delay it.
Why did the judge rule the provision unlawful?
The ruling turned on procedure, not on the merits of gender-affirming care.
Judge Gorton found that the Department of Health and Human Services had unlawfully revised the scope of essential health benefits without submitting a report Congress requires — one that must contain a certification from the chief actuary of the Centers for Medicare & Medicaid Services. The Massachusetts Attorney General’s Office described the holding in the same terms: the administration modified the essential health benefit categories “without following the procedures required by federal law.”
That framing matters for readers trying to gauge how durable the outcome is. A ruling grounded in a missing procedural step addresses how the rule was made, not whether an agency could ever pursue a similar policy through a compliant process. Readers following the broader pattern of wins and losses in these cases may find our earlier piece on lower-court outcomes running against higher-court results a useful companion.
What parts of the rule did the court leave standing?
Most of what the states challenged in this particular case survived.
Judge Gorton upheld four other marketplace provisions the states had contested: the rules governing the ACA’s open enrollment period; the failure-to-reconcile policy for advance premium tax credits; the premium adjustment methodology; and wider allowable ranges around plans’ actuarial values. Healthcare Dive characterized the decision as otherwise a win for HHS — a description consistent with the arithmetic of the order.
The full account of the decision is available in Healthcare Dive‘s report, “Federal judge vacates Trump admin restrictions on ACA gender-affirming care.”
Who brought the case, and how does it fit with the other ACA litigation?
A coalition of 21 states filed the suit in July 2025, challenging nine separate provisions of the final rule.
Massachusetts Attorney General Andrea Joy Campbell co-led the coalition of 20 other states, and California Attorney General Rob Bonta also co-led the effort. The states argued the rule would make coverage harder to obtain through the ACA, raise costs for states, and weaken the law’s core protections.
Seven of the nine challenged provisions had already been vacated in separate litigation — City of Columbus et al. v. Kennedy et al., in the U.S. District Court for the District of Maryland. Per the Massachusetts Attorney General’s Office, the essential health benefits provision had not previously been vacated and was not among the provisions challenged in the Maryland case, which is why this ruling reached it.
“This victory blocks the Trump Administration’s attempt to make gender-affirming care more expensive and less accessible,” Campbell said in a statement issued by her office on August 18. Bonta, per Healthcare Dive, likewise called the ruling a major victory, noting that it returns gender-affirming care to the ACA’s financial protections in states that allow the care.
Does this mean every insurance plan must now cover gender-affirming care?
No. The decision does not require every insurer to cover gender-affirming care, and it does not resolve how current benefits should be administered.
That limit is central to reading the ruling accurately. The vacatur restores the essential-health-benefit framework and the cost protections attached to it in states that permit the care. It does not itself settle whether federal or state regulators will direct insurers to revise benefit documents, recalculate cost sharing, or revisit claims already processed under the now-vacated policy.
AHIP, the health insurance industry’s largest trade group, said plans will need guidance from CMS and from states on how to proceed with any coverage changes or adjustments.
How does this ruling relate to the separate Medicaid decision?
They are distinct actions affecting different populations and different programs.
Days before this ruling, CMS finalized a separate policy ending federal Medicaid and Children’s Health Insurance Program funding for some gender-affirming services for minors, effective October 13. States may continue paying for those services with their own funds. We cover that rule in detail in our report on the CMS Medicaid and CHIP funding restriction. That policy is unaffected by the Massachusetts decision, which concerns commercial coverage sold through the ACA marketplaces.
The two moving in opposite directions within the same week is characteristic of the present moment: federal courts and federal agencies are producing outcomes that do not point the same way. We covered another recent example in our report on the Ninth Circuit’s decision reviving a DOJ subpoena for patient records, and the wider policy arc in our coverage of federal action after Skrmetti.
What happens next?
The immediate open question is whether the administration appeals or seeks a stay, and HHS has not said.
Healthcare Dive reported that HHS did not respond to questions about whether it plans to appeal or seek a stay, or about how issuers and states should administer existing plans while the ruling remains in effect. Until regulators issue guidance, insurers are operating without a clear instruction on claims processed under the vacated provision.
For a longer view of how coverage, recognition, and legal status have shifted over time, our Reference Library history section collects the background this year’s rulings are being written against.
Frequently asked questions
When was the ACA gender-affirming care ruling issued?
The U.S. District Court for the District of Massachusetts issued the decision on August 14, 2026. The Massachusetts Attorney General’s Office announced the outcome in a press release dated August 18, 2026, and trade and mainstream outlets reported on it in the days that followed.
Which rule did the court vacate?
The court vacated one provision of the Trump administration’s “Marketplace Integrity and Affordability” rule — the part that would have excluded certain types of gender-affirming care from the Affordable Care Act’s essential health benefit categories. The rest of the rule was not disturbed by this order.
What does “essential health benefit” mean under the ACA?
It refers to ten categories of care that non-grandfathered individual and small-group plans must cover. Spending on those benefits counts toward the annual out-of-pocket maximum, and the benefits cannot have annual or lifetime dollar limits—protections that do not attach to services outside the categories.
Does the ruling require insurers to cover gender-affirming care?
No. The decision does not require every insurer to cover gender-affirming care, and it does not resolve how insurers should administer existing benefits. It restores the essential-health-benefit designation and its cost protections in states that allow the care.
Which states brought the lawsuit?
A coalition of 21 states filed suit in July 2025. Massachusetts Attorney General Andrea Joy Campbell co-led the coalition of 20 other states, and California Attorney General Rob Bonta also co-led the effort. The states challenged nine provisions of the rule.
Is this the same as the Medicaid gender-affirming care rule?
No. A separate CMS policy finalized days earlier ends federal Medicaid and CHIP funding for some gender-affirming services for minors beginning October 13, with states free to continue paying from their own funds. That policy is unaffected by this ruling, which concerns ACA marketplace plans.
Will the ruling be appealed?
That is not yet known. HHS did not respond to press questions about whether it intends to appeal or seek a stay, or about how insurers and states should administer existing plans while the decision stands. Any appeal would go to the U.S. Court of Appeals for the First Circuit.
This report is a factual summary of a court decision and related agency action. It is not legal or medical advice. Readers with questions about their own coverage should consult their plan documents or a qualified professional.
Continue Exploring
More in Politics